Please assess the completion status of the following clinical trial:

Trial Title: A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented chronic genotype-1 hepatitis C infection and with plasma HCV RNA of \> 100,000 IU/mL at screening~* Patients that have not been treated before for HCV~* Patients that are of childbearing potential or have a partner of childbearing potential should agree to use 2 effective methods of contraception~Exclusion Criteria:~* Patients with cirrhosis or evidence of hepatic decompensation~* Co-infection with the human immunodeficiency virus (HIV)~* Any contraindication to Pegasys or Copegus therapy~* History of, or any current medical condition which could impact the safety of the patient in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 75 mg 12 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
- TMC435 75 mg 24 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
- TMC435 150 mg 12 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
- TMC435 150 mg 24 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
- Placebo 24 Wks + PR48 (Type: PLACEBO_COMPARATOR): Participants will receive Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).